Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
November 13 2019 - 7:00AM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of
tumor drug resistance, today announced that members of the
management team will present at the following investor
conferences:
- Jefferies 2019 London Healthcare Conference on Wednesday,
November 20 at 2:40 PM GMT in London
- Piper Jaffray 31st Annual Healthcare Conference on Thursday,
December 5 at 9:30 AM ET in New York
A live webcast of both events will be available on the “Events
and Presentations” page in the “Investors” section of the Company’s
website at
https://investors.deciphera.com/news-events/events-presentations. A
replay of the webcast will be archived on the Company’s website for
90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
addressing key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, and
agents designed to inhibit reprogramming of cancer cell metabolism.
We have used our platform to develop a diverse pipeline of
tumor-targeted, immuno-targeted, and metabolism-targeted drug
candidates designed to improve outcomes for patients with cancer by
improving the quality, rate and/or durability of their responses to
treatment
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191113005129/en/
Investor Relations: Jen Robinson Deciphera
Pharmaceuticals, Inc jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners
David.Rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024